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Nitric oxidePulmonary arterial hypertension (PAH) is associatedwith refractory vasoconstriction and impairedNO-mediated
vasodilatation of the pulmonary vasculature. Vascular tone is regulated by light chain (LC) phosphorylation of
both nonmuscle (NM) and smooth muscle (SM) myosins, which are determined by the activities of MLC kinase
and MLC phosphatase. Further, NO mediated vasodilatation requires the expression of a leucine zipper positive
(LZ+) isoform of the myosin targeting subunit (MYPT1) of MLC phosphatase. The objective of this study was
to deﬁne contractile protein expression in the pulmonary arterial vasculature and vascular reactivity in PAH. In
severe PAH, compared to controls, relative LZ+MYPT1 expression was decreased (100 ± 14% vs. 60 ± 6%,
p b 0.05, n = 7–8), and NM myosin expression was increased (15 ± 4% vs. 53 ± 5% of total myosin, p b 0.05,
n = 4–6). These changes in contractile protein expression should alter vascular reactivity; following activation
with Ang II, force activation and relaxation were slowed, and sustained force was increased. Further, the
sensitivity to ACh-mediated relaxation was reduced. These results demonstrate that changes in the pulmonary
arterial SMcontractile protein expressionmayparticipate in themolecularmechanismproducing both the resting
vasoconstriction and the decreased sensitivity to NO-mediated vasodilatation associated with PAH.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
In PAH, the pulmonary vasculature is characterized by a resting
vasoconstriction and impairment of NO-mediated vasodilatation, and
only ~20% of PAH patients respond to conventional vasodilators [1,2].
For untreated patients with PAH, median survival is 2.8 years [3].
Currently, 5-year survival for WHO category I patients is 61%, and the
1-year mortality is ~15% [4]. In addition, pulmonary hypertension con-
tributes to themorbidity andmortality of patientswith both pulmonary
and cardiovascular diseases [5].
An increase in the proliferation/apoptosis ratio has been suggested
to produce PAH. It is hypothesized that widespread endothelial apo-
ptosis results in selection of apoptosis-resistant endothelial precursor
cells that proliferate and eventually form plexiform lesions [1,2,6]. In
the media, pulmonary artery SM cell apoptosis is suppressed and
proliferation is enhanced [3,7,8]. These changes result in the histological
ﬁndings present in PAH, including intimal hyperplasia, adventitial
proliferation and plexiform lesions, which produce an elevation of
pulmonary arterial pressure (reviewed in [4,9]). Despite these known
factors that contribute to the molecular mechanism that produceser,MN55905, USA. Tel.:+1 507
vich).
. Open access under CC BY-NC-SA licenPAH, the contribution of dysfunction at the level of SM contractility to
the pathogenesis of PAH has not been elucidated.
Vascular tone is regulated by regulatory light chain (LC) phos-
phorylation of both nonmuscle (NM) and smooth muscle (SM) myosins,
which aredeterminedby the activities ofMLCkinase andMLCphosphatase
[5,10–12]. MLC kinase is regulated by Ca2+-calmodulin, whereas MLC
phosphatase activity is regulated by several signaling pathways including
those mediated by both NO and Rho kinase [11]. MLC phosphatase is a
trimeric enzyme consisting of catalytic, 20 kDa and MYPT1 subunits [10].
Alternative splicing of a 3′ exon produces MYPT1 isoforms that differ by
the presence/absence of a LZ (LZ+/LZ−, [13]), and a LZ+MYPT1 isoform
is required for NO-mediated activation of MLC phosphatase [14]. We
have demonstrated that, in isolation, a decrease in LZ+MYPT1 expression
results in a decrease in the sensitivity of SM to NO-mediated relaxation
[14]. Thus, changes in LZ+MYPT1 expression contribute to themechanism
that regulates the sensitivity of the vasculature to NO-mediated relaxation
[14–16]. Further, LZ+MYPT1 isoform expression decreases in heart failure,
pre-eclampsia, and portal hypertension [15–18], and thus, a decrease in
LZ+MYPT1 expression contributes to the decrease in sensitivity to NO
associated with these diseases.
Recent evidence suggests that NM myosin also participates in the
force maintenance phase of SM contraction and hence to the regulation
of vascular tone. Compared with SMmyosin, the kinetics of NMmyosin
are slow [19,20]. Consequently, NM myosin spends a majority of its
kinetic cycle attached to actin to support force [19], and changes in
NM myosin expression have been demonstrated to inﬂuence vascular
tone [21].se.
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proteins in pulmonary arterial smooth muscle and pulmonary vascular
reactivity in PAH. Our data suggest that MYPT1 and NM myosin
expression is altered in PAH, and that these changes contribute to the
molecular mechanism that produces PAH.
2. Material and methods
2.1. MCT rat model of PAH and pulmonary artery preparation
The Institutional Animal Care and Use Committee of theMayo Clinic
approved all experimental protocols and animal care, and the study
conformed to the guidelines of the National Institutes of Health.
We used the rat model of monocrotaline (MCT)-induced PAH, in
which a single MCT injection leads to severe PAH within 4 wks [22].
The pathological changes occurring in the lung vasculature as well
PAH progression in this model have been well characterized [23,24].
Brieﬂy, PAH was induced in male Sprague–Dawley rats weighing
250 g by a single i.p. injection of MCT (60 mg/kg). Control rats were
injected with normal saline. The rats were sacriﬁced at 2 and 4 wks
after injection. Prior to sacriﬁce, RV pressure was assessed using a 22G
catheter connected to a pressure transducer and inserted into RV from
abdominal cavity via the diaphragm. Subsequently, the heart was
exposed by a midline thoracotomy and the heart and lungs were
harvested. Tissue was then placed in Ca2+-free Tyrode's solution (in
mM: 135 NaCl, 4 KCl, 1 MgCl2, 0.33 Na2HPO4, 0.03 EDTA, 10 glucose,
10 HEPES; pH 7.4) on ice. The main, right and left pulmonary
arteries, and their lobar branches were isolated (with an intact
endothelium) and cleaned of connective tissue. PA tissuewas processed
immediately as appropriate for studies described below. The RV was
separated from the LV and the interventicular septum (IVS). The RV
wt and RV to (LV + IVS) ratio (Fulton index) was used to assess RV
hypertrophy. The left lung was placed in the neutral buffered 10%
formalin and submitted to the Mayo Clinic Pathology Department for
further processing.
2.2. Echocardiography
Echocardiography was performed at baseline, 2-wk, and 4-wk
time points using the Vevo 770 ultrasound system (VisualSonics), as
previously described [23]. Brieﬂy, transthoracic 2D, M-mode, and
pulsed wave (PW) Doppler were obtained with a 17 MHz broadband
scan head. M-mode and 2D modalities were applied to measure RV
free-wall thickness during end diastole using the right parasternal
short-axis view. Main pulmonary artery diameter was measured at
the level of pulmonary outﬂow tract during midsystole using superior
angulation of the parasternal short-axis view. PW Doppler was used to
obtain pulmonary artery ﬂow velocity time integral (VTI) and to
measure the pulmonary artery acceleration time (PAAT). For these
measurements, the sample volume was centrally positioned within
the main pulmonary artery, just distal to the pulmonary valve with
orientation of the beam parallel to ﬂow.
2.3. Pathology
The lung tissue preserved in the neutral buffered 10% formalin was
processed by the Mayo Clinic Pathology Department. The tissue was
embedded in parafﬁn, cut in 5 μm slices (thickness), and stained with
either haematoxylin and eosin (H&E) or Van Gieson. Morphometric
analysis of pulmonary vasculature was performed using ImageJ.
2.4. Mechanical studies
Mechanical studies were conducted following protocols established
in our laboratory as described previously [25]. Brieﬂy, isolated main
pulmonary artery and the right and left pulmonary arteries were cutin 4 rings of ~2 mm (length). Rings isolated from the same animal
were used for both mechanical and molecular studies. For the mech-
anical studies, rings were transferred to a vessel chamber containing
continuously oxygenated physiological saline solution (PSS, in mM:
140 NaCl, 3.7 KCl, 2.5 CaCl2, 0.81 MgSO4, 1.19 KH2PO4, 0.03 EDTA, 5.5
glucose, 25 HEPES; pH 7.4), mounted on a DMT (Mulvany) 4-channel
myograph system and stretched to Lo (the length for maximal force,
which was determined in control preparations). Following the stretch
to Lo, the rings were allowed to equilibrate for 30 min, and then the
passive force was recorded. The rings were stimulated to contract
with 80 mM KCl depolarization (in mM: 64.5 NaCl, 80 KCl, 2.5 CaCl2,
0.81 MgSO4, 1.19 KH2PO4, 0.03 EDTA, 5.5 glucose, 25 HEPES; pH 7.4)
or 1 μM Ang II. Active force is deﬁned as the increase in force above
the resting passive force, and the force traces are the active component
of force. To determine the sensitivity to ACh-mediated relaxation, the
SM was depolarized (80 mM KCl) and after force reached a steady
state, the dose response relationship for ACh-mediated relaxation was
determined by sequential addition of a higher [ACh].
2.5. Determination of NM and SM expression
NM and SMmyosin expressionwas determined using 2D SDS-PAGE
as described [21,25]. We have previously demonstrated that this
technique resolves the nonphosphorylated and phosphorylated SM
myosin light chain (SM LC) and NM myosin light chain (NM LC) as
four distinct spots [21]. Brieﬂy, rings from the main PA, the right and
left PAs and their lobar branches were manually homogenized in 2D
gel extraction buffer (7 M urea, 2 M thiourea, 4% CHAPS, 1% 3–5.6
immobilized pH gradient (IPG) buffer and EDTA-free Protease Inhibitor
and PhosStop Phosphatase Inhibitor (Roche, Indianapolis, Ind., USA)).
The homogenates were cleared of lipids and extraneous salts using the
2D gel clean up kit (GE Healthcare). The acidic halves of 13-cm IPG
DryStrip gels (pH3–5.6 NL) were rehydrated in the presence of suitable
amounts of sample in rehydration buffer solution (7 M urea, 2 M
thiourea, 2% CHAPS, 0.5% pH 3.5–5 IPG buffer, 0.002% bromophenol
blue and 12 μM/ml Destreak Reagent) for at least 10 h in the ‘face-
down’ mode on the Ettan IPG rehydration tray and then resolved by
isoelectric focusing in the ‘face-up’ mode on an Ettan IPGphor III (GE
Healthcare). Following isoelectric focusing, the gel strips were equil-
ibrated in 6 M urea, 50 mM Tris–HCl, pH 6.4, 30% glycerol, 2% (w/v)
SDS and 0.002% bromophenol blue, ﬁrst containing 130 mM DTT for
15min and then containing 135mM iodoacetamide for 15min before
undergoing sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) for protein separation by molecular weight using the Bis-
Tris buffering system with 12% gels (29:1). Subsequently, resolved 2D
SDS-PAGE gels were silver stained. Gels were scanned using a Personal
Densitometer SI, and the spots were quantiﬁed using ImageQuant TL
software. The two spots closest to the anode (spots 1 & 2) represent
the phosphorylated and nonphosphorylated NM LC and the two spots
nearest the cathode (spots 3 & 4) represent the phosphorylated and
nonphosphorylated SM LC. The expression of NM myosin is calculated
as [(1 + 2) / (1 + 2 + 3 + 4)] × 100%], while LC phosphorylation for
SMmyosin is (3/(3+4))×100% and LCphosphorylation for NMmyosin
is (1 / (1+2))×100% [21].
2.6. Immunoblotting
Western blots were used to determine protein expression in
pulmonary arteries of normal versus rats with PAH as previously
described [21,25]. Brieﬂy, pulmonary arterial rings were homogenized
in an SDS sample buffer. The total extracted protein was resolved by
SDS-PAGE using the Bis-Tris buffering system with 8% gels (29:1). The
actin band on Coomassie stained gels was used to normalize protein
loading among samples. After SDS-PAGE separation, proteins were
transferred onto a Hybond™ (GE Healthcare) membrane. MYPT1,
LZ+MYPT1, SM myosin, NMIIA, NMIIB, and actin were visualized
1 mN
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KCl PSS
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AngII
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Fig. 1. Pulmonary vascular reactivity is altered in severe PAH. (A) Representative tracings
of active force for a pulmonary artery ring from control (black) and rats with severe PAH
(red, MCT at 4wks) activated with 80mMKCl depolarization. Compared to controls, both
contraction and relaxation phases were prolonged in pulmonic SM from rats with severe
PAH. (B) Representative tracings of active force for pulmonary arterial rings from control
(black) and severe PAH (red) stimulatedwith Ang II. Compared to controls, the contractile
properties of pulmonary arterial SM from ratswith severe PAHweremore tonic displaying
slower rates of force activation and relaxation, and an increase in the level of force
maintenance.
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Signaling), a mouse mAb anti-LZ+MYPT1 isoform [15,26], a mouse
mAb anti-SM myosin (MYH11 sc-6956 from Santa Cruz), a rabbit
polyclonal anti-NMIIA (M8064 Sigma), a rabbit polyclonal anti-NMIIB
(M7939 Sigma), and a rabbit polyclonal anti-actin (A2066, Sigma) Ab.
Following washing, the blots were incubated with Cy3-labeled anti-
mouse IgG (Jackson Immunoresearch) or Cy5-labeled anti-rabbit IgG
(GE Life Sciences). Blots were scanned on a Typhoon 9410 imager, and
analyzed using ImageQuant TL software. All blots were normalized for
actin, and to normalize expression across blots, one of the sample
preparations was chosen as a standard sample and loaded on all
Western blots. The level in the controls was set as 1.
2.7. Statistical analysis
All data are presented as mean ± SEM, and n represents the
number of animals in each group. Student's t-test was performed to
evaluate signiﬁcant differences between the two groups. Differences
were considered to be signiﬁcant at p b 0.05, and when multiple
comparisons between groups were necessary, a Bonferroni correction
was performed.
3. Results
3.1. Physiology
At 2 wks, there were no signiﬁcant hemodynamic differences
between control and MCT treated rats. However as reported by many
others [23,27], 4 wks following MCT injection, the rats had ﬁndings
consistent with the development of RV hypertrophy and severe
pulmonary hypertension (Supplemental Table 1). Although the wet
wt of pulmonary arteries was no different at 2 wks, at 4 wks, the
pulmonary artery wet wt was higher in MCT treated rats vs. controls
(0.040±0.005 g vs. 0.090±0.010 g, p b 0.05, n=4). Histological lung
examination was performed on a subset of animals at weeks 2 and 4;
at week 4, multiple small pulmonary vessels with increased wall
thickness appeared throughout the lung parenchyma, which were not
apparent at 2 wks (data not shown). These ﬁndings are consistent
with the development of severe PAH at 4 wks following MCT ad-
ministration [23].
3.2. Mechanical Studies
In PAH, the pulmonary vasculature is characterized by a resting
vasoconstriction and impairment of NO-mediated vasodilatation.
Thus, we determined the reactivity of pulmonary arterial SM in control
andMCT treated rats. Total force is the sum of active and passive forces.
Passive force was similar in control and MCT treated animals at 2wks,
but at 4wks, passive force was signiﬁcantly higher in the MCT treated
animals (2.6 ± 0.2 mN vs. 3.0 ± 0.1 mN, p b 0.05, n = 4), which is
consistent with a signiﬁcant change in the architecture of the smooth
muscle strip.
Following KCl depolarization, force rose to a plateau in control and
MCT treated rats, and force declined with return of the preparation to
PSS. At 2 wks, there was no signiﬁcant difference in the rate of force
activation between control and MCT rats (t1/2; 0.30 ± 0.05 min vs.
0.19±0.03min, p N 0.05, n=4 per group) but, relaxation was slower
(t1/2; 0.95 ± 0.11 min vs. 1.74 ± 0.31 min, p b 0.05) and force
maintenance was lower (1.98±0.21mN vs. 1.48±0.28mN, p b 0.05)
in the MCT treated rats. At wk 4 (Fig. 1A), the MCT rats had a lower
sustained active force (2.45 ± 0.24 mN vs. 1.28 ± 0.31 mN, p b 0.05,
n = 4 per group) as well as slower rates of force activation (t1/2;
0.29±0.02min vs. 0.83±0.26min, pb 0.05) and force relaxation (t1/2;
1.23±0.09min vs. 2.16±0.17min, pb0.05).
Stimulation with Ang II resulted in a phasic contractile response in
pulmonary arterial rings from control animals; force rapidly rose to apeak before falling to a lower steady state. At 2 wks, there was no
difference in the phasic response; t1/2 for contraction (0.40±0.04min
vs. 0.45±0.07min, pN0.05, n=4 per group) and the t1/2 for relaxation
(3.9±0.2min vs. 4.0±0.2, pN0.05) were not different. However at wk
4, the force proﬁle following Ang II stimulation was signiﬁcantly
differentwhen compared to control (Fig. 1B); the rate of force activation
and relaxation was signiﬁcantly slower for MCT treated animals (t1/2
contraction: 0.30 ± 0.01 min vs. 0.40 ± 0.03 min, p b 0.05 & t1/2
relaxation: 2.3± 0.2min vs. 8.7 ± 0.7min, p b 0.05, n= 4 per group).
Further, although peak active force was lower (2.87 ± 0.33 mN vs
0.65 ± 0.21 mN, p b 0.05), at 15 min following Ang II stimulation,
force maintenance for pulmonary arterial SM from the rats with severe
PAH was signiﬁcantly higher (0.16 ± 0.05 mN vs. 0.41 ± 0.18 mN,
p b 0.05, n = 4–5 per group). Thus for agonist activation, force
maintenance (both the active and the total force (2.76 ± 0.05 mN vs
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to controls.
We investigated NO-mediated signaling by determining the dose–
response relationship of ACh-induced relaxation of pulmonary arterial
rings. At 2 wks, ACh produced a dose dependent SM relaxation for
both control and MCT treated rats (data not shown). However at
4 wks, ACh did not produce a signiﬁcant relaxation of pulmonary SM
from MCT treated animals (Fig. 2). This contrasted with control
preparations, in which ACh produced a dose-dependent relaxation;
relaxation averaged 9.8±2.3% at 0.1 μM ACh and 23±3% at 1 μM ACh.
3.3. Molecular studies
NM myosin has been shown to contribute to force maintenance in
SMandhence to the regulation of vascular tone,whereas the expression
of the LZ+MYPT1 isoform is required for NO-mediated SM relaxation.
Thus to explain the changes in vascular reactivity present in severe
PAH (Figs. 1, 2), we examined whether PAH was associated with a
change in the expression of NMmyosin and MYPT1.
The absolute expression of NMvs. SMmyosinwas determined by 2D
SDS-PAGE, which separates the non and phosphorylated SM and NM
myosins as four distinct spots (Fig. 3). At 2 wks, NM expression
represented ~15–20% of total myosin expression and there was no
signiﬁcant difference in the expression of NM myosin in control vs.
MCT-treated rats (16 ± 2% vs. 23 ± 3%, p N 0.05, n = 4). However at
wk 4, there was a signiﬁcant increase in NM myosin expression in
MCT-treated rats (15±4% vs. 53±5%, p b 0.05, n=5–6); with severe
PAH, NMmyosin expression was equal to that of the SMMHC. Western
blots were consistent with the 2D SDS-PAGE ﬁndings. At 4wks (Fig. 4),
there was a signiﬁcant decrease in SMMHC expression (1.00±0.07 vs.
0.70±0.06, pb0.05, n=5–6), whereas there was a signiﬁcant increase
in both NMIIA (1.00±0.06 vs. 2.71±0.55, pb0.05, n=4–6) and NMIIB
(1.00±0.06 vs. 1.25±0.05, p b 0.05, n=4–6) expression. In addition,
there was no difference in the resting phosphorylation of the regulatory
LCs of either SM (15±4% vs 7±3%, pN0.05) or NM (3±3% vs 3±3%,
pN0.05) myosin.
Both total MYPT1 and LZ+MYPT1 isoform expression was assessed
with Western blots using a polyclonal MYPT1 Ab and a mAb anti-
LZ+MYPT1 Ab [15,26]. At 2wks, there was no difference in the relative
expression of the LZ+MYPT1 isoform, deﬁned as LZ+MYPT1/total
MYPT1, between control and MCT treated rats. However in pulmonary
arterial SM fromMCT rats with severe PAH (wk 4), relative LZ+MYPT1
expressionwas signiﬁcantly reduced (1.00±0.14 vs. 0.60±0.06, n=7–
8, Fig. 5), and the decrease in relative LZ+MYPT1 expression was
predominantly due to an increase in total MYPT1 expression (total
MYPT1/actin; 1.00±0.10 vs 1.60±0.10).
4. Discussion
PAH is a syndrome that is characterized by increased pulmonary
vascular resistance. The histological ﬁndings in PAH include vascularACh (µM) 0.001 0.01 0.1 1 10
10 mKCl
10
0%
Control
MCT
Fig. 2.The sensitivity toACh-mediated relaxation is reduced in severe PAH. Representative
tracings for active force for pulmonary arterial rings during ACh-mediated relaxation from
control (black) and rats with severe PAH (red) are overlaid to more easily compare the
response to ACh. In controls, ACh produced a dose dependent relaxation, while there
was no signiﬁcant response to ACh in the preparations from animals with severe PAH.remodeling and angioproliferative plexiform lesions [9]. However in
PAH, the contribution of changes in SM contractile protein expression
to the increase in pulmonary vascular resistance has not been deﬁned.
In SM, others have demonstrated that NM myosin is responsible for
the sustained force response [28,29] and a decrease in NM myosin
expression, in isolation, decreases vascular tone [21]. Additionally,
changes in the expression of LZ+/LZ− MYPT1, in isolation, have been
demonstrated to produce changes in the sensitivity to NO-mediated
vasodilatation [14]. Thus, our data suggests that changes in the ex-
pression of pulmonary arterial SM contractile proteins, namely the
increase in NMmyosin and decrease in relative LZ+MYPT1 expression,
will produce abnormalities of vascular reactivity and these changesmay
contribute to the pathogenesis of PAH.
Within themedia of thepulmonary arteries, PAHcould be associated
with an increase in ﬁbroblasts and/or myoﬁbroblasts. However for both
MCT and hypoxia induced PAH, there is a proportional increase in both
SM and connective tissues [30,31]. Additionally in PAH, the staining of
the cells within the media is consistent with an increase in smooth
muscle cells [30,31]. Thus in our study,wewould argue that the increase
in the ratio of NM/total myosin observed in severe PAH is due to an
increase in the expression of NM myosin in the SM cells. This increase
in NM myosin could mark a transition from a contractile to a prolif-
erative SM phenotype. However, the increase in NMmyosin expression
would also alter SM contractility [19–21,25,32,33].
In severe PAH, the signiﬁcant increase in passive force suggests
that there is a change in tissue architecture, possibly including the
orientation of the smooth muscle cells within the tissue. These changes
in smooth muscle orientation and tissue architecture would alter the
force length relationship of the pulmonary smooth muscle strips [34],
which could have affected our results; active force would be reduced
if the MCT treated preparations were not at Lo.
We performed our experiments using larger pulmonary vessels
isolated from the main pulmonary artery up to the lobar arteries. It
was technically not feasible to dissect the resistance vessels due to
their small diameter (b100 μm), but dissection of the larger arteries
allowed us to use the same vessels for both molecular and contractility
studies. It is unclear if the changes we demonstrated in the pulmonary
arterial vessels reﬂect changes that occur in the pulmonary resistance
vessels. However, we have demonstrated that cardiac ischemia alters
both NM myosin and LZ+MYPT1 expression in the resistance vessels
isolated from the mesenteric circulation [25], suggesting that the
changes in NM myosin and MYPT1 expression documented in the
pulmonary arteries (Figs. 3–5) could reﬂect changes in protein ex-
pression in the resistance vessels of the pulmonary vasculature.
4.1. NM myosin expression
With the development of severe PAH, 4 wks after MCT injection,
there is a 3.5 fold increase of NM myosin expression (15 ± 4% vs.
53 ± 5%, Figs. 3, 4), which is accompanied by markedly abnormal
vascular reactivity; both force activation and relaxation are prolonged,
with a markedly increased and prolonged phase of force maintenance
for Ang II stimulation (Fig. 1). Others have suggested that the expression
of NM myosin increases in hypoxia induced PAH [33]. However in this
study [33], NM and SM MHCs were identiﬁed only based on molecular
weight. The SM1 and SM2 smooth muscle MHC isoforms are readily
resolved and separated from NM myosin [35]. NMIIA has a predicted
MW of 228kDa and NMIIB has three isoforms, with predicted MWs of
229, 230 & 232 kDa. But, NMIIA and NMIIB are not separated by SDS
PAGE [36], and thus, it is unclear if the two bands (MW 196 kDa &
190 kDa) denoted as NM myosin in Packer's study [33] represent
NMIIA and NMIIB. Nonetheless, our study is the ﬁrst to document that
NM myosin expression signiﬁcantly increases in severe PAH.
The kinetics of NMmyosin are slower than SMmyosin [19,20,32]. In
the presence of actin, NMmyosin has a high ADP afﬁnity and it spends
majority of kinetic cycle attached to actin [19,20]. For NMIIB, the rate of
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Fig. 3.NMmyosin expression increaseswith the development of PAH. 2D SDS-PAGE resolves the NMmyosin and SMMHC as 4 distinct spots. Spots 1 and 2 represent phosphorylated and
nonphosphorylated NM LC, respectively, while spots 3 and 4 represent phosphorylated and nonphosphorylated SM LC. The expression of NM myosin is calculated as [(1 + 2) /
(1+2+3+4)]×100% [21]. Bar graphs summarize NMmyosin expression in the pulmonary artery inMCT-treated rats at wk 2 and 4 (*, pb0.05). (A) 2weeks followingMCT treatment.
(B) 4weeks following MCT treatment.
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actin does not accelerate ADP release, but instead enhances ADPbinding
[19,37]. For NMIIA, the rate of ADP release is an order of magnitude
faster than the steady state ATPase [20], which implies that compared
to NMIIB, NMIIA spends a smaller fraction of its ATPase cycle bound
to actin [19,35]. However when compared to SM myosin, these
kinetic properties (Vmax; NMIIB 0.1 s−1 [19], NMIIA 1.2 s−1 [20], SM
MHC 6 s−1 [32]) allow NM myosin to remain attached to actin for a
greater fraction of AMATPase cycle, which would increase the number
of NM myosin cross-bridges attached to actin and predict that an
increase in NM myosin expression would result in sustained force at
low energetic cost. Thus, NM myosin should contribute to force
maintenance in SM.
Mechanical studies support these biochemical predictions. Morano
and colleagues [28] demonstrated that bladder SM from transgenic
mice lacking SM myosin contract, albeit very slowly and without
the transient peak force; i.e., the contraction was phasic in WT mice
and tonic in SM KO mice. The KO animals did not express SM myosin,
and the expression of NM myosin was similar in SM KO and WT
mice. These data suggest that SM myosin is responsible for the rapid
initial rise in force while NM myosin participates in the sustained
phase of force maintenance. Similarly, force maintenance in the aorta
of heterozygous NMIIB KO mice was lower than that in WT mice [21],
and in WT mice, inhibition of NM myosin decreases force maintenance
[38].
Our force tracings in severe PAH are similar to those in transgenic
mice lacking SM myosin [28,29]. For Ang II stimulation, force had a
slower rate of activation and a markedly prolonged relaxation phase,
which when compared to control, resulted in a signiﬁcant increase in
sustained force (Fig. 1B). Similarly for KCl depolarization of preparations
from rats with severe PAH, the rates of both force activation andrelaxation were slow (Fig. 1A). In bladder smooth muscle from WT
mice, Lofgren et al. [29] demonstrated that force displayed a phasic
response with a rapid peak before falling to a lower level of force
maintenance, while in SM KO mice, force slowly rose to a plateau,
which was 70% lower than that in WT mice. These results may suggest
that SMmyosin is required for a rapid increase in force, and NMmyosin
is primarily responsible for the maintenance of force. Thus, there could
be differences for tonic and phasic contractions, which would be
consistent with our results. For the tonic contractile response to KCl,
the lack of a rapid increase in force could lead to a lower level of force
maintenance. Further in normal rats and rats with PAH, the pulmonary
vasculature is not innervated [39,40], which could question the
physiologic signiﬁcance of depolarization. For the phasic response to
Ang II stimulation, the decrease in the expression of SM myosin would
be expected to blunt the peak force, while the increase in NM myosin
would be expected to increase force maintenance, which is consistent
with our results (Fig. 1B).
These results agree with recent evidence that suggests that NM
myosin regulates vascular tone [20,21,37,38]. In aortic SM from
heterozygous NM IIB KOmouse, we have demonstrated that a decrease
in NM myosin expression (13% vs. 6% of total myosin expression)
resulted in a 25% reduction in maintenance force [41]. Similarly, we
have also demonstrated that inhibition of NMmyosin with blebbistatin
decreased force maintenance by 8% in the mouse bladder and 24%
in the mouse aorta [38]. Further, Morano and Arner's groups [29]
demonstrated that the bladder from the SM MHC KO mouse produced
~11% of the force compared to WT.
Others have also reported a decrease in peak force in pulmonary
smooth muscle isolated from animals with PAH [30,42–44]. However
for agonist activation, it is unclearwhy these other studies only reported
peak force rather than sustained force, since force maintenance is more
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Fig. 4. SM MHC and NM myosin expression change with the development of severe PAH. Immunoblotting demonstrates the changes in SM MHC, NMIIA and NMIIB expression in
pulmonary artery in MCT rats with severe PAH (*, p b 0.05).
152 E.A. Konik et al. / Journal of Molecular and Cellular Cardiology 65 (2013) 147–155important for the regulation vascular tone, and thus, vascular resistance.
Nonetheless for agonist activation of pulmonary arterial SM isolated
from animals with severe PAH, the passive, active and total components
of sustained force are signiﬁcantly increased, which would produce an
increase in both pulmonary vascular tone and resistance.4.2. MYPT1 expression
Our data also demonstrate that severe PAH is associated with a
signiﬁcant decrease in relative LZ+MYPT1 expression (Fig. 5) and a
decrease in the sensitivity of pulmonary artery SM to NO mediated
relaxation (Fig. 2). MLC phosphatase controls SM relaxation via
dephosphorylation of the regulatory myosin light chains. Its regulatory
subunit, MYPT1, is a key target of the NO/cGMP/PKG vasodilator-
signaling pathway. Alternative splicing generates LZ+and LZ−MYPT1
isoforms, and only the LZ+MYPT1 isoform undergoes site-speciﬁc
phosphorylation by cGMP-dependent protein kinase (PKG), which is
required for NO/cGMP-mediated activation of MLC phosphatase [41].
Further, we have demonstrated that a decrease in LZ+MYPT1 ex-
pression, in isolation, results in a decrease in the sensitivity of SM to
NO [14]. Therefore, the decrease in relative LZ+MYPT1 expression
that occurs with severe PAH would decrease PKG mediated activationof MLC phosphatase and result in a decrease in the sensitivity of the
pulmonary vasculature to NO-mediated relaxation.
The requirement of an intact endothelium for ACh mediated
vasodilatation has been established [45]. MCT is thought to damage
the endothelial cells, and a decrease in endothelial function would
produce a decrease in sensitivity to ACh mediated relaxation [45]. We
would expect that MCT induced endothelial dysfunction should occur
relatively early after MCT injection, which is not consistent with our
results. Two wks after MCT injection, before the development of PAH,
there was no change in either LZ+MYPT1 expression or the sensitivity
to ACh-mediated relaxation. Four wks after MCT injection, concurrent
with the development of severe PAH, there was a signiﬁcant decrease
in relative LZ+MYPT1 expression (Fig. 5) that was accompanied by
severely blunted relaxation in response to ACh (Fig. 2). This decrease
in sensitivity to NO would decrease ﬂow-mediated vasodilatation,
which in addition to the increase in NM myosin, would also produce
an increase in vascular tone.
Others have demonstrated a decrease in LZ+MYPT1 expression in
cultured pulmonary SMC exposed to hypoxia [46]. Additionally, a
decrease in the ratio of LZ+MYPT1/MYPT1 expression has been
suggested to mark the transition from a phasic to tonic SM contractile
phenotype [47]; SM with tonic contractile properties have increased
vascular tone, similar to that observed in patients with PAH. The
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This decrease may represent a pathological change that produces PAH.
Alternatively, the increase in total MYPT1 expression demonstrated in
this study could represent an attempt to increase ﬂow mediated
vasodilatation and decrease pulmonary vascular tone as an adaptive
response to the resting vasoconstriction produced by both the increase
in NM myosin expression and proliferative changes that occur in the
pulmonary vasculature. In either scenario, we have demonstrated that
although total MYPT1 increases, relative LZ+MYPT isoform expression
falls. This is a result of an increase in LZ-MYPT1 expression, which
would bind PKG, and decrease PKG interaction with and subsequent
phosphorylation of the LZ+MYPT1 isoform, leading to a decrease in
the sensitivity to NO, and thus, contribute to the vascular abnormalities
that produce PAH.
In cultured SMCs, we have previously demonstrated that adenoviral
infection with LZ+/LZ− MYPT1 isoforms produces a change in sen-
sitivity to cGMP mediated smooth muscle relaxation [14], and thus in
isolation, changes in LZ+/LZ− MYPT1 regulate the sensitivity to cGMP
mediated smooth muscle relaxation. Further, changes in relative
LZ+MYPT1 isoform expression (LZ+MYPT1/total MYPT1) are a predom-
inant mechanism for altered NO-sensitivity in vascular diseases such as
heart failure [15,16], portal hypertension [17], preeclampsia [18], as well
as nitrate tolerance [48]. Importantly, pathological LZ+MYPT1 isoform
expression changes can be prevented. In the rat model of heart failure,
captopril treatment maintained the normal expression of LZ+MYPT1
[16] by decreasing the activation of p42/44 MAPK [49], which results in
preservation of the normal sensitivity to cGMP-mediated SM relaxation
[16]. Thus for the treatment of heart failure, the beneﬁcial effects of
blocking Ang II signaling, compared to other vasodilatators, could be
due to altering the vascular phenotype by increasing relative LZ+MYPT1
expression and normalizing vascular reactivity.4.3. Implications for human disease
In PAH, aberrant signaling, altered protein expression levels, and
histological ﬁndings have been documented [9,50]. However, the
molecular mechanism that produces PAH has yet to be elucidated. Our
results demonstrate that changes in both NM myosin and relative
LZ+MYPT1 expression could contribute to the molecular mechanism
that produces PAH in the MCT treated rat. Only 20% of PAH patients
respond to conventional vasodilators [1]. Further, whether a patient
with PAH will have signiﬁcant pulmonary vasodilatation to NO cannot
be predicted, and patients that lack a response to NO have a poorer
prognosis [51]. Our results could suggest that patients that maintain
normal NM myosin and LZ+MYPT1 expression would respond to NO
based vasodilators, while those patients with an increase in NMmyosin
expression and a decrease in LZ+MYPT1 expression may have a poor
prognosis.
In heart failure, treatment with ACE inhibitors [16] or ARBs [49]
maintains the normal expression of LZ+MYPT1 and sensitivity to NO.
There is evidence in both animal and human clinical studies supporting
a role of the renin angiotensin system in the development and pro-
gression of PAH, but the use of ACE inhibitors or ARBs in PAH is
controversial [52–56]. Recent evidence has demonstrated that activa-
tion of guanylate cyclase improves hemodynamics in PAH [57,58],
which suggests that there is a defect at the level of the SM, possibly an
alteration in the expression of NM myosin and LZ+MYPT1 in the
pulmonary vasculature, which contributes to the pathogenesis of
PAH. Thus for PAH, therapies aimed at preventing and/or reversing
the changes in NM myosin and MYPT1 in pulmonary arterial smooth
muscle could restore NO-mediated vasodilatation and decrease pul-
monary vascular tone, which would improve both symptoms and
prognosis.
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Our results suggest a novel paradigm that contributes to the
mechanism that produces PAH. We propose that abnormalities at the
level of the SM contribute to the mechanism for refractory vasocon-
striction and impaired NO-mediated vasodilatation in PAH: (1) an
increase in NM myosin expression results in a prolonged, sustained
contraction that produces an increase in pulmonary vascular resistance;
and (2) a decrease in relative LZ+MYPT1 expression results in a decrease
in the sensitivity to NO-mediated relaxation. Vascular remodeling,
angioproliferative plexiform lesions and excessive vasoconstriction are
hallmarks of human PAH. Whereas proliferation is difﬁcult to reverse,
the changes in protein expression that contribute to both pulmonary
arterial vasoconstriction and an impaired response to NO-mediated
relaxation could be prevented and/or reversed with therapy aimed at
preserving normal contractile protein expression in pulmonary arterial
smooth muscle.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2013.10.009.
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